Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Management of symptomatic hyponatremia (e.g., severe hyponatremia with neurological symptoms),Reduction of intracranial pressure in cerebral edema (off-label, but commonly used),Hypovolemia and hyponatremia due to salt depletion (off-label use)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion of 3% sodium chloride at a rate of 1-2 m L/kg/hour, with a typical rate of 50-100 m L/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 m L/hour, with careful monitoring of serum sodium (increase not >8-10 m Eq/L per 24 hours).
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Not applicable: sodium and chloride are endogenous electrolytes; administered dose mixes with body pools and is eliminated via renal excretion with a half-life dependent on renal function and hydration status. In euvolemic individuals with normal renal function, the terminal elimination half-life of excess sodium is approximately 6–12 hours.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Sodium chloride is not metabolized; it is distributed in extracellular fluid and excreted primarily by the kidneys. No hepatic metabolism.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal (essentially 100%): sodium and chloride ions are excreted unchanged in urine. No biliary or fecal elimination of intact drug; sodium and chloride are obligately filtered and variably reabsorbed based on volume status and renal function.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
0%: sodium and chloride ions are not protein bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Total body water (0.6 L/kg): sodium distributes primarily in extracellular fluid (0.2 L/kg); chloride distributes similarly. Clinical meaning: reflects rapid equilibration with the extracellular space.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% (bioequivalent to endogenous electrolytes). No oral or other relevant routes for hypertonic saline; oral administration would have variable absorption and is not used.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose adjustment for renal impairment based on GFR. Use with caution in patients with renal failure due to risk of fluid overload and hypernatremia. Monitor renal function and fluid balance closely.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment for hepatic impairment based on Child-Pugh score. Use with caution in patients with cirrhosis due to risk of ascites and fluid overload. Monitor serum sodium and fluid status.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous 3% sodium chloride: 0.5-1 m L/kg over 30-60 minutes, with a maximum rate of 1 m L/kg/hour, titrated to serum sodium. Typical dose for severe hyponatremia: 1-2 m L/kg/hour. Monitor serum sodium every 1-2 hours.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Lower initial infusion rates (e.g., 25-50 m L/hour) due to decreased renal function and higher risk of fluid overload. More frequent monitoring of serum sodium and hemodynamic status. Avoid rapid correction (>8 m Eq/L per 24 hours).
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None
None
Risk of osmotic demyelination syndrome (central pontine myelinolysis) if serum sodium is corrected too rapidly; use with caution in patients with heart failure, renal impairment, or pre-existing hypernatremia; monitor serum sodium, chloride, and fluid status; avoid extravasation as it may cause tissue necrosis.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypernatremia; fluid overload; severe renal impairment with oliguria or anuria; pre-existing hyperchloremia; concurrent use of medications that cause sodium retention (e.g., corticosteroids) should be considered relative contraindication; not for use as a maintenance fluid.
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No direct food interactions. However, dietary sodium restriction is typically indicated in hyponatremia management, but not during active treatment with 3% saline.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Sodium chloride 3% is a hypertonic solution used intravenously for correction of severe hyponatremia. In pregnancy, no teratogenic effects have been reported; however, rapid correction of hyponatremia can cause osmotic demyelination syndrome, which may affect both mother and fetus. First trimester: no known teratogenic risk. Second and third trimesters: cautious use indicated as maternal fluid and electrolyte imbalances can impact fetal homeostasis.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Sodium chloride is a normal constituent of breast milk. Intravenous infusion of hypertonic saline may transiently increase maternal serum sodium, but negligible transfer into milk is expected. M/P ratio not established. Generally considered compatible with breastfeeding, but monitor infant for signs of electrolyte imbalance if maternal therapy is prolonged or high-dose.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy does not typically require dose adjustment of hypertonic saline. However, pregnancy-associated plasma volume expansion and altered renal function may influence sodium handling; monitor serum sodium levels frequently. Use with caution in preeclampsia due to increased risk of fluid overload.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Hypertonic saline (3%) is used for rapid correction of symptomatic hyponatremia (e.g., seizures, coma). Infuse via central line to avoid phlebitis; use an infusion pump. Monitor serum sodium every 2-4 hours; do not exceed 8-12 m Eq/L rise in 24 hours to prevent osmotic demyelination. Reserve for ICU setting.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously to raise low sodium levels.,You will have frequent blood tests to monitor your sodium levels.,Report any new headache, confusion, or muscle weakness immediately.,Do not stop the infusion or adjust the rate on your own.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is a Electrolyte that works by Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is: Intravenous infusion of 3% sodium chloride at a rate of 1-2 m L/kg/hour, with a typical rate of 50-100 m L/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 m L/hour, with careful monitoring of serum sodium (increase not >8-10 m Eq/L per 24 hours).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride 3% is a hypertonic solution used intravenously for correction of severe hyponatremia. In pregnancy, no teratogenic effects have been reported; however, rapid correc. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.